Sonnet BioTherapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Stockholders??? Equity (Deficit) (Details Narrative)

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)							1 Months Ended		12 Months Ended
	Dec. 10, 2024	Nov. 07, 2024	Jun. 21, 2024	Jun. 19, 2024	May 02, 2024	Oct. 26, 2023	Jul. 31, 2025	Oct. 31, 2023	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2023
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of common stock									$ 7,803,453	$ 3,896,577
Issuance of share, value									7,806,497	3,976,382
Financing costs incurred									$ 465,200	370,426
Private placement							$ 2,000,000.0
Share price							$ 1.156		$ 1.21
Gross proceeds offerings							$ 5,000,000.0
Warrants							100,000
Proceeds from convertible note							1,400,000
Proceeds from issuance of warrants							600,000		$ 2,022,785
Debt discount							600,000
Liquidation preference value									$ 1,000
Preferred stock conversion price									$ 1.25
Cumulative dividend percentage									6.00%
Proceeds from warrant exercises									$ 11,185,971	2,983,769
Warrant, shares									14,910,028
Purchase and Registration Rights Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock avialable to be sold									$ 24,700,000
Underwriting Agreement [Member] \| Chardan Capital Markets LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold		155,000
Proceeds from offering		$ 4,200,000
Business Combination Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Private placement									5,500,000
Convertible notes							$ 2,000,000.0
Proceeds from warrant exercises									$ 3,000,000.0
Business Combination Agreement [Member] \| Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold									5,500
Number of shares converted							2,000
Inducement Offer Letter Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price								$ 12.80
Warrant exercise price decrease								$ 9.60
Proceeds from issuance of warrants			$ 2,900,000
Aggregate number of shares issued								353,562
Warrant, shares									187,500
Shares released from abeyance, shares									187,500
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares							865,052
Exercise price							$ 1.156
Issuance of share, value									$ 120	$ 17
Sale of common stock, net of issuance costs, shares							1,730,104		1,203,520	167,987
Net share settlement of warrants, shares									1,209	94,288
Common Stock [Member] \| Purchase and Registration Rights Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold									153,020	4,706
Issuance of share, value					$ 25,000,000.0
Volume weighted average price discount percentage					4.00%
Net proceeds									$ 200,000	$ 100,000
Common Stock [Member] \| Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Financing costs incurred									$ 500,000	$ 400,000
Common Stock [Member] \| Business Combination Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold									4,400,000
Warrants to purchase shares									8,800,000
Exercise price									$ 1.25
Aggregate number of shares issued							3,200,000
Prefunded Warrant [Member] \| Underwriting Agreement [Member] \| Chardan Capital Markets LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares		956,111							1,611,112
Offering price per share		$ 4.4999
Exercise price		$ 0.0001
Common Warrant [Member] \| Underwriting Agreement [Member] \| Chardan Capital Markets LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares		2,222,222
Offering price per share		$ 4.50
Exercise price		$ 4.50
Warrants term		5 years
Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of common stock, net of issuance costs, shares									1,209	94,288
Net share settlement of warrants, shares									2,419	96,090
Number of warrant exercised									5,018,060	355,937
Proceeds from warrant exercises									$ 11,200,000	$ 3,000,000.0
Warrant, shares										187,500
New Common Stock [Member] \| Inducement Offer Letter Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant, shares				703,125
Existing Warrant [Member] \| Inducement Offer Letter Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price								$ 12.80
Warrant exercise price decrease				$ 9.60
Warrant, shares				354.994
Existing Warrant Issued in June 2023 [Member] \| Inducement Offer Letter Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant, shares											28,409
Existing Warrant Issued in June 2023 [Member] \| Inducement Offer Letter Agreements [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price											$ 118.78
Expiration date											Jun. 21, 2029
Existing Warrant Issued in June 2023 [Member] \| Inducement Offer Letter Agreements [Member] \| Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price											$ 12.40
Expiration date											Dec. 30, 2026
New Common Stock Warrant [Member] \| Inducement Offer Letter Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price				$ 12.40
Warrants term				5 years
Dr Richard Kenney [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold							160,000
Warrants to purchase shares							86,505
Private placement							$ 200,000
Dr Richard Kenney [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares							320,000
Placement Agent [Member] \| Inducement Offer Letter Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares				14,142
Exercise price				$ 14.88
Warrants term				5 years
Holder [Member] \| Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Forfeited warrants, shares										4,302
October Offering [Member] \| Underwriters [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of common stock						$ 3,900,000
Warrants to purchase shares						10,664
Exercise price						$ 16.00
Warrants term						5 years
October Offering [Member] \| Underwriters [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold						163,281
October Offering [Member] \| Underwriters [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares						192,187
Offering price per share						$ 12.7992
Exercise price						$ 0.0008
October Offering [Member] \| Underwriters [Member] \| Common Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares						710,931
Offering price per share						$ 12.80
Exercise price						$ 12.80
Warrants term						5 years
October Offering [Member] \| Underwriters [Member] \| June 2024 Inducement Offer [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price decrease						$ 9.60
Registered Direct Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Offering price per share	$ 2.23
Proceeds from offering	$ 3,400,000
Registered Direct Offering [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Offering price per share	$ 2.2299
Registered Direct Offering [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold	768,000
Warrants to purchase shares	317,325
Exercise price	$ 0.0001
Registered Direct Offering [Member] \| Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares	1,085,325
Exercise price	$ 2.10
Warrants term	5 years
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Offering price per share	$ 2.23
Private Placement [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold	127,500
Warrants to purchase shares	545,500								323,000
Exercise price	$ 0.0001
Private Placement [Member] \| Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares	673,000
Exercise price	$ 2.10
Warrants term	5 years